| name | Nedocromil Sodium |
| classification | Leukotriene Modifiers (Mast cell stabilizer) |
| pharmacokinetics | | absorption | Poorly absorbed from the gastrointestinal tract, primarily acting locally. | | distribution | Concentrates in the lungs. | | metabolism | Minimal hepatic metabolism, primarily excreted unchanged in the urine. | | elimination | Renal excretion. |
|
| suggested dosage | | adult | Inhaler, typically 2 puffs 4 times daily. | | other dosages | Adjust dosage as needed, based on individual response and severity of symptoms. | | important notes | Follow the prescribing doctor's instructions carefully and use the inhaler properly, as the effectiveness depends on correct use. |
|
| indications | | 1 | Prophylaxis and treatment of chronic asthma. | | 2 | Management of exercise-induced bronchospasm. |
|
| safety in pregnancy | | category | Category B (Animal studies have not shown risk to the fetus, but there are no adequate studies in humans.) | | notes | Nedocromil sodium is generally considered to be safe in pregnancy when prescribed according to guidelines; however, a pregnant woman should always consult her physician and obtain individualised advice. |
|
| safety in breastfeeding | | category | Limited data available. | | notes | Nedocromil is excreted in breast milk in low concentrations. The decision to use this medication in a breastfeeding mother needs to be taken in consultation with a doctor who assesses risks and benefits to both mother and child. |
|
| side effects | | 1 | Cough | | 2 | Throat irritation | | 3 | Headache | | 4 | Nausea | | 5 | Vomiting | | 6 | Sore throat | | 7 | Dysphonia (Hoarseness) | | 8 | Upper respiratory tract infections | | 9 | Local oral/pharyngeal reactions (e.g., mouth pain, swelling) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to nedocromil sodium or other components of the formulation. | | 2 | Severe respiratory infections |
|
| interactions | | 1 | Concurrent use of other bronchodilators is common and usually safe. |
|
| warnings and precautions | | 1 | Proper technique for inhaler use is crucial to maximize effectiveness and minimize side effects. | | 2 | Patients should be monitored closely for adverse reactions. | | 3 | Caution in patients with pre-existing pulmonary conditions. |
|
| additional information | | mechanism of action | Reduces mast cell degranulation and inhibits the release of inflammatory mediators. | | administration | Inhalation only. | | patient education | Advise patients to always follow the instructions provided by their doctor, including using the inhaler technique properly and ensuring they understand the correct frequency and duration of treatment. Patients should immediately report any adverse symptoms. | | age specific dosing | Appropriate dosage adjustments may be necessary depending on the patient's age. Consult a physician for accurate and individualised guidance. |
|
